Intuitive Surgical, Inc. (NASDAQ:ISRG) is Prospect Hill Management LLC's 5th Largest Position

Prospect Hill Management LLC grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,125 shares of the medical equipment provider's stock after buying an additional 800 shares during the period. Intuitive Surgical accounts for about 3.9% of Prospect Hill Management LLC's holdings, making the stock its 5th biggest holding. Prospect Hill Management LLC's holdings in Intuitive Surgical were worth $7,491,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ISRG. AlphaCore Capital LLC lifted its holdings in shares of Intuitive Surgical by 4.2% during the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock valued at $235,000 after buying an additional 18 shares during the period. Accredited Investors Inc. increased its holdings in Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after buying an additional 19 shares during the last quarter. Second Line Capital LLC increased its holdings in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after buying an additional 19 shares during the last quarter. Colonial Trust Co SC raised its position in Intuitive Surgical by 8.8% in the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock worth $128,000 after acquiring an additional 20 shares during the period. Finally, Crown Wealth Group LLC grew its holdings in Intuitive Surgical by 4.8% during the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock valued at $218,000 after purchasing an additional 20 shares during the period. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ISRG. Citigroup reiterated a "buy" rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Truist Financial decreased their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. BTIG Research set a $566.00 target price on shares of Intuitive Surgical and gave the stock a "buy" rating in a report on Monday, July 14th. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their price target for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. Finally, Robert W. Baird decreased their price target on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $592.86.

Intuitive Surgical Trading Up 0.5%

NASDAQ:ISRG traded up $2.46 during trading hours on Friday, hitting $518.62. 1,903,997 shares of the stock were exchanged, compared to its average volume of 1,666,315. The firm's fifty day moving average price is $535.90 and its 200 day moving average price is $536.21. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $616.00. The company has a market cap of $185.88 billion, a P/E ratio of 76.04, a P/E/G ratio of 5.50 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same quarter last year, the business posted $1.50 earnings per share. Equities analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 188 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the transaction, the executive vice president directly owned 5,224 shares in the company, valued at $2,695,113.84. This trade represents a 3.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares of the company's stock, valued at $510,740.77. This trade represents a 19.23% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,998 shares of company stock worth $2,611,577. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.